Exact Sciences CORP

Exact Sciences Corporation has finalized its merger with Abbott Laboratories, becoming a direct wholly-owned subsidiary of Abbott.

Exact Sciences Corporation has received all regulatory approvals for its merger with Abbott Laboratories, with closing anticipated on March 23, 2026.

Exact Sciences Corporation announced record fourth quarter and full year 2025 financial results, driven by strong growth in Screening and Precision Oncology revenue, alongside significant advancements in its cancer diagnostic pipeline and progress towards its merger with Abbott Laboratories.

Exact Sciences Corporation accelerates 2025 annual bonuses and vests certain equity awards for its named executive officers to mitigate potential tax impacts related to its pending merger with Abbott Laboratories.

Abbott Laboratories will acquire Exact Sciences for $105 per share in cash, totaling $21 billion, to become a leader in the rapidly growing cancer screening and precision oncology diagnostics market.

Exact Sciences announced record third-quarter 2025 revenue of $851 million, a 20% increase, and raised its full-year 2025 guidance, driven by strong performance in its Screening and Precision Oncology segments and the launch of its Cancerguard test.

Exact Sciences Corporation reported a 20% year-over-year revenue increase in Q3 2025, driven by strong Cologuard and Oncotype DX test volumes, alongside the launch of new cancer screening and diagnostic products.

Exact Sciences reported significant revenue growth and reduced net losses in Q2 2025, driven by Cologuard and Oncotype test adoption, while advancing its diagnostic pipeline and announcing a major collaboration with Freenome.

Exact Sciences Corporation announces an 11% increase in revenue for the first quarter of 2025, driven by growth in both screening and precision oncology segments.

Exact Sciences Corp. saw a 13% year-over-year revenue increase in the third quarter of 2024, driven by growth in Cologuard and Oncotype DX tests, while also achieving key milestones in its product pipeline.

Exact Sciences reports a strong second quarter with revenue growth, increased testing volumes, and progress in its pipeline development.

Exact Sciences saw a revenue increase in the first quarter of 2024, driven by growth in Cologuard and Oncotype DX tests, but the company still reported a net loss.

Exact Sciences delivered over 4.6 million cancer test results in 2024, grew revenue by 10%, and secured FDA approval for Cologuard Plus.

Exact Sciences Corporation achieved significant milestones in 2023, including revenue growth, positive cash flow from operations, and advancements in its product pipeline.

Brian Baranick, EVP of Exact Sciences, reported the disposition of all his common stock and derivative holdings following the company's acquisition by Abbott Laboratories.

Exact Sciences' SVP, General Counsel & Secretary, James Herriott, reported the disposition of all his Exact Sciences common stock, options, and restricted stock units following the company's merger with Abbott Laboratories.

Exact Sciences' EVP and CFO, Aaron Bloomer, reported the disposition of common stock and restricted stock units following the company's merger with Abbott Laboratories.

Exact Sciences' EVP of Human Resources, Sarah Condella, reported the disposition of all her common stock, options, and restricted stock units following the company's acquisition by Abbott Laboratories.

Exact Sciences CEO Kevin T. Conroy reported significant changes in his beneficial ownership of company securities following the merger with Abbott Laboratories, converting equity and options into cash.

Jacob Orville, EVP at Exact Sciences, reported the disposition of common stock, stock options, and restricted stock units following the company's merger with Abbott Laboratories' subsidiary.

Exact Sciences Corporation's Board unanimously recommends stockholders vote FOR the proposed merger with Abbott at the upcoming Special Meeting on February 20, 2026.

Exact Sciences Corporation will be acquired by Abbott Laboratories for $105.00 per share in cash, representing a significant premium to recent trading prices.

Exact Sciences Corporation accelerates 2025 annual bonuses and equity awards for its named executive officers to mitigate tax impacts related to its pending merger with Abbott Laboratories.

Exact Sciences announces its planned acquisition by global healthcare leader Abbott, expected to close in Q2 2026, with a per-share value of $105.

Exact Sciences announced an agreement to be acquired by Abbott, a move expected to close in Q2 2026, aiming to expand patient reach and accelerate cancer diagnostics.

Exact Sciences CEO Kevin Conroy discusses the strategic benefits of the proposed acquisition by Abbott Laboratories, emphasizing global reach and shared values.

The Vanguard Group filed an amendment to its Schedule 13G for Exact Sciences Corp, reporting 0% beneficial ownership due to an internal reporting realignment.

Exact Sciences Corporation and its subsidiary, Genomic Health, Inc., have reported a 12.0% beneficial ownership stake in MDxHealth SA ordinary shares.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in Exact Sciences Corp as of November 28, 2025.

Capital World Investors has filed an amended Schedule 13G, reporting an 8.5% beneficial ownership in Exact Sciences Corp. common stock.

Wellington Management Group LLP and its affiliates have reported a 3.04% beneficial ownership stake in Exact Sciences Corporation, holding 5,747,093 shares of common stock.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 9.8% in Exact Sciences Corp, totaling over 18.5 million shares.